{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:56:06Z","timestamp":1780469766924,"version":"3.54.1"},"reference-count":18,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Advances in Wound Care"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>SN514 is a thermolysin-like enzyme under development as a debrider. Preclinical and non-clinical studies supported a first in human healthy volunteer study to predict the need for protection of periwound skin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach:<\/jats:title>\n                    <jats:p>\n                      Pharmacologic activity testing compared\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      digestion of collagen, fibrin, and elastin with relevant enzymes. A Yorkshire pig model of burn injury was used to evaluate debridement over 10 days and effects on intact skin. A human 21-day cumulative irritation study using Webril patches taped to the backs of 38 healthy adult volunteers compared four enzyme concentrations (0.10%, 0.20%, 0.40%, and 0.80% w\/w) with the hydrogel vehicle, saline (low irritant control), and 0.2% sodium lauryl sulfate (positive irritant control) using randomized placements and blinded evaluation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      SN514 showed excellent digestion of fibrin, elastin, and collagen\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      . Burn wound studies in Yorkshire pigs showed efficient eschar debridement with minimal periwound erythema. Direct treatment on intact porcine skin for 5 days produced no to limited erythema. The preclinical findings of minimal irritation with SN514 were verified by a Phase 1 first-in-human 21-day cumulative skin irritation test. Irritation was observed to increase stepwise by concentration, confirming formulation accuracy. Each enzyme concentration was found to be \u201cpossibly mild in use\u201d (Berger and Bowman method). No treatment emergent adverse events were observed during the study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Innovation:<\/jats:title>\n                    <jats:p>A fast-acting enzyme with a favorable irritation profile, prepared as a stable, ready to use hydrogel formulation, overcomes many recognized shortcomings of enzyme debriders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The overall findings support clinical dose range testing for tolerance and preliminary efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/wound.2024.0215","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T10:01:38Z","timestamp":1737712898000},"page":"589-599","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of a New Enzymatic Debrider (SN514-066b) on Eschar Protein Digestion, Burn Wound Debridement, and Healthy Skin Irritation"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0550-8757","authenticated-orcid":false,"given":"Herbert B.","family":"Slade","sequence":"first","affiliation":[{"name":"SERDA bv, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry T.","family":"Reece","sequence":"additional","affiliation":[{"name":"ALS Global, Irving, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick D.","family":"McCoy","sequence":"additional","affiliation":[{"name":"McCoy Clinical Consulting LLC, Grapevine, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Roche","sequence":"additional","affiliation":[{"name":"Macro Biologics, Fort Worth, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksa V.","family":"Jovanovic","sequence":"additional","affiliation":[{"name":"Smith &amp; Nephew plc, Fort Worth, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[{"name":"Suzhou MicroPort Regenerative Medicine Technology Co., Ltd, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasreen","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Kenatha Scientific Consulting LLC, Fort Worth, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,18]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4377-2786-9.00011-4"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-4179(99)00117-5"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-475X.2009.00545.x"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(98)70045-3"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1099\/ijs.0.030346-0"},{"key":"e_1_3_4_7_2","unstructured":"U.S. Department of Health and Human Services. Guidance for Industry - Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products. U.S. Food and Drug Administration: 1999."},{"issue":"1","key":"e_1_3_4_8_2","first-page":"15","article-title":"In vitro evaluation of enzymatic debridement of burn wound eschar","volume":"73","author":"Silverstein P","year":"1973","unstructured":"Silverstein P, , Ruzicka FJ, , Helmkamp GM, et al. In vitro evaluation of enzymatic debridement of burn wound eschar. Surgery, 1973; 73(1):15\u201322.","journal-title":"Surgery"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56120706"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.4960"},{"key":"e_1_3_4_11_2","unstructured":"DPT Laboratories. In vitro efficacy study on thermolysin as a wound debriding agent compared with other proteases including papain trypsin collagenase and elastase. 2002."},{"key":"e_1_3_4_12_2","unstructured":"Healthpoint Biotherapeutics. Evaluation of Various Topical Formulations Containing Thermolysin as Compared to Bromelain and Papain\/Urea Treatments in the Digestion of Escars in Porcine Burn Wounds. 2011."},{"key":"e_1_3_4_13_2","unstructured":"Smith & Nephew. Evaluating the Effects of Various SN514 Topical Formulations on the Digestion of Porcine Thermal Wound Eschars. 2018."},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/15569528209051516"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-475X.2002.10603.x"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jbcr\/iraa111"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)08751-8"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2016.1141418"},{"key":"e_1_3_4_19_2","volume-title":"Chronic Cutaneous Ulcer and Burn Wounds - Developing Products for Treatment","author":"U.S. Department of Health and Human Services","year":"2006","unstructured":"U.S. Department of Health and Human Services. Chronic Cutaneous Ulcer and Burn Wounds - Developing Products for Treatment. Food and Drug Administration: Rockville, Maryland USA; 2006."}],"container-title":["Advances in Wound Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/wound.2024.0215","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/wound.2024.0215","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/wound.2024.0215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:47:44Z","timestamp":1770630464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/wound.2024.0215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1089\/wound.2024.0215"],"URL":"https:\/\/doi.org\/10.1089\/wound.2024.0215","relation":{},"ISSN":["2162-1918","2162-1934"],"issn-type":[{"value":"2162-1918","type":"print"},{"value":"2162-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}